Marvell Stock Just Got a Stunning Price Target Hike on the AI Boom

Marvell Technology (MRVL) shares fell 2% to $281.34 on October 7 despite a $425 price target from Oppenheimer. The company projected fiscal 2028 revenue near $20B and fiscal 2029 custom-chip sales above $12B, aiming for $70B-$90B in total revenue by fiscal 2031. Management expects adjusted earnings to exceed $30 per share at the midpoint. The stock is 128.84% above the $122.94 GF Value estimate, raising execution risks.

Marvell Technology (MRVL) shares fell 2% to $281.34 on October 7 after Oppenheimer set a $425 price target. Management projected fiscal 2028 revenue near $20B, fiscal 2029 custom-chip sales above $12B, and $70B-$90B in total revenue by fiscal 2031. The stock is 128.84% above the $122.94 GF Value estimate, raising execution risks.

BMO Capital raised Marvell Technology's (MRVL) price target to $325 from $250, citing higher AI infrastructure opportunities. The firm kept a Market Perform rating. Marvell updated its fiscal 2028 revenue target to $20B from $18B and data-center revenue to $18B from $15B, with fiscal 2031 projections of $70B-$90B revenue and over $30 EPS.

Marvell Technology (MRVL) projects revenue of $70B-$90B by 2031, surpassing Intel's (INTC) recent $57B. Wall Street previously estimated $47B. Shares rose 9.52% intraday. CEO Matt Murphy cites strong AI bookings. Google's (GOOGL) deal could add $120B by 2033. Intel reported 25.42% Q2 growth. Risks include customer concentration and wafer supply.

Marvel Biosciences reported preliminary preclinical results showing MB-204 improved autism-related behaviors in a mouse model, outperforming Istradefylline. Full statistical analysis is pending.

Marvell raised its FY2028 revenue outlook to $20B, up from $18B, and set a FY2031 target of $70B-$90B. Applied Materials shows sales acceleration due to high demand for AI semiconductor chips. Both companies benefit from data center expansion and chip manufacturing growth.